UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 389

Sortiert nach

1143P Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy

Annals of oncology, 2022-09, Vol.33, p.S1072-S1073

2022

Link zum Volltext

Verfügbarkeit prüfen

1286P Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC

Annals of oncology, 2020-09, Vol.31, p.S831-S831

2020

Link zum Volltext

Verfügbarkeit prüfen

1293MO Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial

Annals of oncology, 2023-10, Vol.34, p.S746-S746

2023

Link zum Volltext

Verfügbarkeit prüfen

1330P Second-line nintedanib + docetaxel for patients with lung adenocarcinoma after first-line chemo-immunotherapy treatment: Updated efficacy and safety results from VARGADO Cohort C

Annals of oncology, 2021-09, Vol.32, p.S1018-S1019

2021

Link zum Volltext

Verfügbarkeit prüfen

1364P Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C

Annals of oncology, 2020-09, Vol.31, p.S872-S872

2020

Link zum Volltext

Verfügbarkeit prüfen

1372P Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) after failure of previous immune checkpoint inhibitor therapy (ICIs): Updated results from the ongoing non-interventional study (NIS) VARGADO (NCT02392455)

Annals of oncology, 2020-09, Vol.31, p.S875-S876

2020

Link zum Volltext

Verfügbarkeit prüfen

1386PDIMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Link zum Volltext

Verfügbarkeit prüfen

1570P - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)

Annals of oncology, 2019-10, Vol.30, p.v646-v647

2019

Link zum Volltext

Verfügbarkeit prüfen

1570PPioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Link zum Volltext

Verfügbarkeit prüfen

186: Superior antitumor in vitro responses of allogeneic matched sibling compared to autologous patient CD8+ T cells

Biology of blood and marrow transplantation, 2007, Vol.13 (2), p.69-69

2007

Link zum Volltext

Verfügbarkeit prüfen

1889: WENDEPUNKT DER AMERIKANISCHEN AUSSENPOLITIK

Historische Zeitschrift, 1965-12, Vol.201 (1), p.57-110

Wehler, Hans-Ulrich

1965

Link zum Volltext

Verfügbarkeit prüfen

1889: WENDEPUNKT DER AMERIKANISCHEN AUSSENPOLITIK: DIE ANFÄNGE DES MODERNEN PANAMERIKANISMUS – DIE SAMOAKRISE

Historische Zeitschrift, 1965-12, Vol.201 (1), p.57-110

Wehler, Hans-Ulrich

1965

Link zum Volltext

Verfügbarkeit prüfen

189TiP Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S800-S801

2021

Link zum Volltext

Verfügbarkeit prüfen

1912TiP NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery

Annals of oncology, 2020-09, Vol.31, p.S1083-S1083

2020

Link zum Volltext

Verfügbarkeit prüfen

1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data

Annals of oncology, 2023-10, Vol.34, p.S1060-S1060

2023

Link zum Volltext

Verfügbarkeit prüfen

200 Jahre amerikanische Revolution und moderne Revolutionsforschung

The Journal of American History, 1977, Vol.64 (3), p.769-770

Schoonover, Thomas

1977

Link zum Volltext

Verfügbarkeit prüfen

29: Rapid expansion of acute myeloid leukemia-reactive cytotoxic T cells from CD8+CD62L+ blood lymphocytes of HLA-matched healthy donors in vitro

Biology of blood and marrow transplantation, 2007, Vol.13 (2), p.13-13

2007

Link zum Volltext

Verfügbarkeit prüfen

297: Establishment of a chimeric NOD-scid/IL2Rγc Null transplantation-model to evaluate graft-vs-host and graft-vs-leukemia immune responses of ex vivo modified human T lymphocyte grafts

Biology of blood and marrow transplantation, 2007, Vol.13 (2), p.108-108

2007

Link zum Volltext

Verfügbarkeit prüfen

297: Establishment of a chimeric NOD-scid/IL2RγcNull transplantation-model to evaluate graft-vs-host and graft-vs-leukemia immune responses of ex vivo modified human T lymphocyte grafts

Biology of blood and marrow transplantation, 2007-02, Vol.13 (2), p.108-108

2007

Link zum Volltext

Verfügbarkeit prüfen

3,3', 4, 4'-tetrachloro-[ 14C]-biphenyl in mouse and mouse fetus

International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes, 1988, Vol.39 (6), p.593-593

1988

Link zum Volltext

Verfügbarkeit prüfen

3,3′,4,4′-tetrachlorobiphenyl and 3,3′,4,4′,5-pentachlorobiphenyl-tissue-localization and metabolic fate in the mouse

Chemosphere (Oxford), 1989, Vol.19 (1), p.809-812

1989

Link zum Volltext

Verfügbarkeit prüfen

3,3′,4,4′‐Tetrachlorobiphenyl in Pregnant Mice: Embryotoxicity, Teratogenicity, and Toxic Effects on the Cultured Embryonic Thymus

Pharmacology & toxicology, 1987-07, Vol.61 (1), p.53-57

1987

Link zum Volltext

Verfügbarkeit prüfen

527 TRENDS IN THE PREVALENCE OF CHILDHOOD AND ADOLESCENT OBESITY IN THE UNITED STATES

Pediatric research, 1985-04, Vol.19 (4), p.198-198A

1985

Link zum Volltext

Verfügbarkeit prüfen

586 Dose Determination of LY2603618 Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Cancer

European journal of cancer (1990), 2012-11, Vol.48, p.179-180

2012

Link zum Volltext

Verfügbarkeit prüfen

759Different rejoining of DNA double strand breaks induced in oxic or hypoxic human skin fibroblasts by ionizing radiation

Radiotherapy and oncology, 1996, Vol.40, p.S193-S193

1996

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 389

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(320)
Mit Volltextzugriff
(359)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

1143P Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy

1286P Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC

1293MO Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial

1330P Second-line nintedanib + docetaxel for patients with lung adenocarcinoma after first-line chemo-immunotherapy treatment: Updated efficacy and safety results from VARGADO Cohort C

1364P Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C

1372P Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) after failure of previous immune checkpoint inhibitor therapy (ICIs): Updated results from the ongoing non-interventional study (NIS) VARGADO (NCT02392455)

1386PDIMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC

1570P - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)

1570PPioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)

186: Superior antitumor in vitro responses of allogeneic matched sibling compared to autologous patient CD8+ T cells

1889: WENDEPUNKT DER AMERIKANISCHEN AUSSENPOLITIK

1889: WENDEPUNKT DER AMERIKANISCHEN AUSSENPOLITIK: DIE ANFÄNGE DES MODERNEN PANAMERIKANISMUS – DIE SAMOAKRISE

189TiP Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC

1912TiP NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery

1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data

200 Jahre amerikanische Revolution und moderne Revolutionsforschung

29: Rapid expansion of acute myeloid leukemia-reactive cytotoxic T cells from CD8+CD62L+ blood lymphocytes of HLA-matched healthy donors in vitro

297: Establishment of a chimeric NOD-scid/IL2Rγc Null transplantation-model to evaluate graft-vs-host and graft-vs-leukemia immune responses of ex vivo modified human T lymphocyte grafts

297: Establishment of a chimeric NOD-scid/IL2RγcNull transplantation-model to evaluate graft-vs-host and graft-vs-leukemia immune responses of ex vivo modified human T lymphocyte grafts

3,3', 4, 4'-tetrachloro-[ 14C]-biphenyl in mouse and mouse fetus

3,3′,4,4′-tetrachlorobiphenyl and 3,3′,4,4′,5-pentachlorobiphenyl-tissue-localization and metabolic fate in the mouse

3,3′,4,4′‐Tetrachlorobiphenyl in Pregnant Mice: Embryotoxicity, Teratogenicity, and Toxic Effects on the Cultured Embryonic Thymus

527 TRENDS IN THE PREVALENCE OF CHILDHOOD AND ADOLESCENT OBESITY IN THE UNITED STATES

586 Dose Determination of LY2603618 Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Cancer

759Different rejoining of DNA double strand breaks induced in oxic or hypoxic human skin fibroblasts by ionizing radiation

Aktive Filter

Suchergebnisse filtern